News Feed Item

MELA Sciences Announces the Results of its Third Clinical Advisory Meeting and the Four Clinical Posters Presented at the Winter Clinical Dermatology Conference

MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced the results of its third company-sponsored Clinical Advisory meeting hosted during the Winter Clinical Dermatology Conference in Hawaii where technical advancements of MelaFind® and future technology development opportunities were discussed and user’s validated its clinical use. MELA Sciences also displayed four clinical posters presentations at the conference, which took place from January 17 – 22, 2014.

The poster presentations reviewed clinical data derived from practice and clinical settings that highlighted how MelaFind has helped dermatologists in the assessment of clinically ambiguous pigmented skin lesions in various patients including young adults, an area of growing concern, and those with atypical mole syndrome. To view the posters and their accompanying abstract please click here.

The poster authored by Dr. Darrell Rigel, titled Physical Properties, Novel Features and Clinical Validation of a Multispectral Digital Skin Lesion Analysis Device for Melanoma, and outlined below was named Poster of the Day on the first day of the conference.

Highlights of the studies and the data shown in the poster presentations are as follows:

Physical Properties, Novel Features and Clinical Validation of a Multispectral Digital Skin Lesion Analysis Device (MSDSLA) for Melanoma Detection - Darrell S. Rigel, MD, MS NYU School of Medicine, New York, NY; Laura Ferris, MD, PhD, University of Pittsburgh. Pittsburgh, PA; Arthur Sober, MD, Harvard University, Boston, MA; Clay J. Cockerell, MD, University of Texas Southwestern, Dallas, TX

  • Retrospective data from the MelaFind pivotal study was used to investigate the MelaFind multispectral images and classifier score result as a tool to differentiate cutaneous melanoma from other pigments skin lesions.
  • Results showed the average classifier scores of melanomas, high-grade lesions, non-melanoma skin cancers, and histologically benign nevi were 3.5, 2.7, 2.6 and 1.6 respectively.
  • Further results showed an increase in the mean classifier score result with each additional clinical characteristic present in the lesion.

Assessing the Predictive Probability of Melanoma and Other High Risk Pigmented Lesions Using Data Provided by a Multispectral digital Skin Lesion Analysis Device - Jane Yoo, MD, MPP, Dept. of Dermatology, Albert Einstein School of Medicine, Bronx, NY; Natalie Tucker, BS, MELA Sciences, Irvington, NY; Darrell S. Rigel, MD, MS, Dept. of Dermatology, NYU School of Medicine, NYC, NY

  • A risk prediction model was built to assess the predictive probability of melanoma or a high-risk lesion for consideration for biopsy based on data obtained from MelaFind.
  • Results show a potential quantitative predictive capacity for presence of melanoma and other high risk pigmented lesions using the MelaFind device.

In addition to presenting data from the four studies, MELA Sciences held its third Clinical Advisory Meeting for current and prospective MelaFind users and thought leaders. In attendance was Dr. Antonanella Calame, dermatologist, dermatopathologist and medical director of Compass Dermatology and Dermatopathology in La Jolla, CA. Dr. Calame, a user of MelaFind, said, “As dermatologists, one of our most important goals is diagnosing melanoma, the deadliest form of skin cancer, at its earliest and most curable stage. The MelaFind system’s images and data analysis tools help dermatologists with one of the most challenging questions we face each day when evaluating clinically ambiguous pigments skin lesions: “Is this lesion atypical enough for me to remove and investigate further via histology?” MelaFind’s analysis of a lesion’s architectural structure gives us access to new information deeper into the skin, where the human eye cannot see, and helps us answer this critical question, improving overall outcomes for both patient and clinician. These tools are available for the first time in medicine and MelaFind is just the beginning. If patient outcomes are our foremost concern, adoption of such technologies should be widespread and soon become part of the standard of care.”

The Winter Clinical Dermatology Conference was conducted over four days and had nearly 400 participants from various fields of dermatology, medical and cosmetic. In discussing the Advances in the Diagnosis of Melanoma, Dr. Laura Ferris credited MelaFind as an important instrument in helping to detect melanoma.

Please follow us:




@MELASciencesIR or @MelaFind







About MELA Sciences, Inc. www.melasciences.com

MELA Sciences is a medical device company developing dermatology diagnostics utilizing state-of-the-art optical imaging. The flagship product is MelaFind®, an FDA, PMA and CE Mark approved, non-invasive diagnostic tool to aid dermatologists in melanoma evaluation and diagnosis. MelaFind® uses a variety of visible to near-infrared light waves to evaluate skin lesions from the surface to 2.5 mm beneath the skin. It provides images and data on the relative disorganization of a lesion's structure that provides substantial additional perspective to aid melanoma diagnosis. MELA is also exploring new potential uses for its core imaging technology and algorithms.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and may contain words such as “seeks,” “look forward,” and “there seems” that suggest future events or trends. These statements are based on our current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from our expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. MELA Sciences assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at www.sec.gov and www.melasciences.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DXWorldEXPO LLC announced today that Kevin Jackson joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Kevin L. Jackson is a globally recognized cloud computing expert and Founder/Author of the award winning "Cloud Musings" blog. Mr. Jackson has also been recognized as a "Top 100 Cybersecurity Influencer and Brand" by Onalytica (2015), a Huffington Post "Top 100 Cloud Computing Experts on Twitter" (2013) and a "Top 50 C...
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities - ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups.
DXWorldEXPO LLC announced today that ICOHOLDER named "Media Sponsor" of Miami Blockchain Event by FinTechEXPO. ICOHOLDER give you detailed information and help the community to invest in the trusty projects. Miami Blockchain Event by FinTechEXPO has opened its Call for Papers. The two-day event will present 20 top Blockchain experts. All speaking inquiries which covers the following information can be submitted by email to [email protected] Miami Blockchain Event by FinTechEXPO also offers s...
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Daniel Jones is CTO of EngineerBetter, helping enterprises deliver value faster. Previously he was an IT consultant, indie video games developer, head of web development in the finance sector, and an award-winning martial artist. Continuous Delivery makes it possible to exploit findings of cognitive psychology and neuroscience to increase the productivity and happiness of our teams.
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.
The standardization of container runtimes and images has sparked the creation of an almost overwhelming number of new open source projects that build on and otherwise work with these specifications. Of course, there's Kubernetes, which orchestrates and manages collections of containers. It was one of the first and best-known examples of projects that make containers truly useful for production use. However, more recently, the container ecosystem has truly exploded. A service mesh like Istio addr...
As IoT continues to increase momentum, so does the associated risk. Secure Device Lifecycle Management (DLM) is ranked as one of the most important technology areas of IoT. Driving this trend is the realization that secure support for IoT devices provides companies the ability to deliver high-quality, reliable, secure offerings faster, create new revenue streams, and reduce support costs, all while building a competitive advantage in their markets. In this session, we will use customer use cases...
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of bus...
DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.